CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced Evaluation and Management of Right-Sided Heart Failure: A Scientific Statement From the American Heart Association Cardiac Resynchronization Therapy and Ventricular Tachyarrhythmia Burden Nocturnal thoracic volume overload and post-discharge outcomes in patients hospitalized for acute heart failure Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure Dapagliflozin for treating chronic heart failure with reduced ejection fraction

Clinical TrialNovember 10, 2018

JOURNAL:N Engl J Med. Article Link

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

SD Wiviott,I Raz,DECLARE–TIMI 58 Investigators. Keywords: Diabetes and Cardiometabolic Disease, Dyslipidemia, Heart Failure and Cardiomyopathies, Prevention, Acute Heart Failure, Hypertension, Smoking

FULL TEXT PDF